NCT05488977

Brief Summary

Lipedema is a fat disorder causing accumulation of subcutaneous adipose tissue particularly in arms and legs, and predominantly affects women. Lipedema likely contributes to an array of other pathologies, including obesity, inflammatory bowel disease, and neurological disorders. Lipedema tissue is often very painful and can severely impair mobility. The condition can also increase the incidence of depression, anxiety, or eating disorders. There seems to be a general impression that lipedema tissue is difficult to reduce by diet, exercise, or bariatric surgery. However, only a few studies have actually explored the effects of exercise training on lipedema. Despite the lack of knowledge, the existing guidelines for lipidemia treatment promote a healthy lifestyle with individually adjusted weight control measures, including physical activity. In general, exercise is known to have an important effect on adipose tissue. Excess adipose tissue causes macrophage infiltration into the adipose tissue leading to continuous low systemic inflammation. This would suggest that there is a systemic inflammatory response in lipedema patients. Increasing IL-6 levels with exercise can decrease the level of proinflammatory TNFalpha synthesized from adipocytes and therefore lead to an anti-inflammatory effect by increasing IL-10 and IL-1ra levels. IL-6 also stimulates fat oxidation by increasing lipolysis. For these reasons, adding an appropriate exercise program to standard treatment might provide additional benefits for lipedema patients. The investigators aim to determine the therapeutic potential of high-intensity interval training (HIIT) on pain, quality of life, body composition, cardiorespiratory fitness and circulating biomarkers in women with lipedema.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2022

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

July 8, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

August 5, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
Last Updated

July 10, 2025

Status Verified

June 1, 2025

Enrollment Period

2.6 years

First QC Date

July 8, 2022

Last Update Submit

July 9, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual analog scale (VAS)

    Visual analog scale (VAS), measured by means of a 0-100 mm, for pain will be used to collect data on pain. VAS has been used in the social and behavioral sciences to measure a variety of subjective phenomena. A VAS is a straight line, whose end anchors indicate the extreme boundaries of the sensation, feeling, or responses to be measured. For example, a VAS to measure pain can be labeled "no pain" on one end and "pain as bad as it could possibly be" on the other end. Subjects respond to the VAS by placing a mark through the line at a position which best represents their current perception of a given phenomenon between the labeled extremes. Although a VAS may be horizontal or vertical and of any length deemed appropriate, its most common form is a 100 mm horizontal line. The VAS is scored by measuring the distance, usually in millimeters, from one end of the scale to the subject's mark on the line.

    Change from baseline to 8 weeks

Secondary Outcomes (21)

  • LYMQOL (Lymphoedema Quality of Life) legs

    Change from baseline to 8 weeks

  • Brief Pain Inventory

    Change from baseline to 8 weeks

  • Short Form Health Survey-36 (SF-36)

    Change from baseline to 8 weeks

  • Glucose

    Change from baseline to 8 weeks

  • HbA1C

    Change from baseline to 8 weeks

  • +16 more secondary outcomes

Study Arms (2)

Exercise training

EXPERIMENTAL

8 weeks of supervised high-intensity interval training (HIIT) that is 4×4 min intervals at 85-95% of maximal heart rate (HRmax) with 3-minute active breaks (\~60 % HRmax) in between intervals, twice a week) on treadmills. In addition, the participants will perform exercise once a week on their own following the correct exercise intensity.

Behavioral: Exercise training

Control

NO INTERVENTION

No intervention. Carry on their normal life.

Interventions

8 weeks of supervised high-intensity interval training (HIIT).

Exercise training

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- can meet for supervised exercise training in Trondheim.

You may not qualify if:

  • eating disorders and/or orthopedic limitations for exercise training

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute for Circulation and Medical Imaging, NTNU

Trondheim, Norway

Location

MeSH Terms

Conditions

Lipedema

Interventions

Exercise

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Øivind Rognmo, PhD

    Norwegian University of Science and Technology

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 8, 2022

First Posted

August 5, 2022

Study Start

July 1, 2022

Primary Completion

February 1, 2025

Study Completion

February 1, 2025

Last Updated

July 10, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations